All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

28

Reset

28 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • ZasocitinibTAK- 279, NDI-034858Phase 317 trials

    Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease

  • TLL-018Phase 38 trials

    Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria

  • EnvudeucitinibPhase 34 trials

    Alumis Inc · Plaque Psoriasis, SLE

  • ICP-332Phase 34 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis

  • TQH3906Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis

  • ICP-488Phase 33 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Plaque Psoriasis Patients, Primary Sjögren's Syndrome, Cutaneous Lupus Erythematosus (CLE)

  • SHR-1314Phase 33 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis

  • CMS-D001Phase 32 trials

    Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis

  • HS-20137QX004NPhase 32 trials

    Hansoh BioMedical R&D Company · Moderate-to-severe Plaque Psoriasis

  • NetakimabPhase 32 trials

    Biocad · Plaque Psoriasis

  • PicankibartPhase 32 trials

    Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis

  • piclidenosonPhase 32 trials

    Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome

  • SYHX1901Phase 32 trials

    CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata

  • WD-890Phase 32 trials

    Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis

  • Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis

  • GNR-068Phase 31 trial

    AO GENERIUM · Plaque Psoriasis

  • Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis

  • QL2106Phase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Plaque Psoriasis

  • SHR-1139Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum

  • ORKA-002Phase 23 trials

    Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)

  • RSS0393Phase 23 trials

    Jiangsu HengRui Medicine Co., Ltd. · Psoriatic Subjects, Plaque Psoriasis in Children, Plaque Psoriasis in Adolescents

  • HSK47388Phase 22 trials

    Haisco Pharmaceutical Group Co., Ltd. · Plaque Psoriasis, Ulcerative Colitis (UC)

  • ORKA-001Phase 22 trials

    Oruka Therapeutics, Inc. · Plaque Psoriasis

  • COL-5671-PROPhase 21 trial

    Coultreon Biopharma · Plaque Psoriasis

  • CS32582Phase 21 trial

    Chipscreen Biosciences, Ltd. · Plaque Psoriasis

  • HS-20118Phase 21 trial

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis

  • LY3972406Phase 21 trial

    Eli Lilly · Plaque Psoriasis

  • LY4100511Phase 21 trial

    DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company · Plaque Psoriasis

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.